Kevin Deboer, DO
Pulmonary Disease · Orlando, FLNPI 1649272402
Payments from drug & device makers
Across 125 payments — averaging $1878.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$126K
- AstraZeneca$61K
- GSK$44K
- Insmed, Inc.$3K
- Actelion Pharmaceuticals US, Inc.$439
- Regeneron Healthcare Solutions, Inc.$224
- plus $974 from 21 others
What the payments were for
- Food & beverage$1,50274%
- Education$49024%
- Gifts$281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 21 | $125,601 |
| AstraZeneca | 18 | $60,684 |
| GSK | 12 | $44,340 |
| Insmed, Inc. | 9 | $2,538 |
| Actelion Pharmaceuticals US, Inc. | 11 | $439 |
| Regeneron Healthcare Solutions, Inc. | 6 | $224 |
| Sanofi | 8 | $178 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $83 |
| Grifols USA, LLC | 4 | $79 |
| Pfizer | 5 | $78 |
| United Therapeutics Corporation | 3 | $68 |
| Verona Pharma, Inc. | 3 | $54 |
| Viatris Specialty LLC | 2 | $50 |
| Philips North America LLC | 3 | $48 |
| AbbVie | 2 | $45 |
| Boehringer Ingelheim | 2 | $44 |
| Portola Pharmaceuticals, LLC | 2 | $41 |
| Bayer | 2 | $31 |
| Advanced Respiratory, Inc | 1 | $28 |
| Vapotherm Inc | 1 | $24 |
| Boston Scientific | 1 | $22 |
| Baxter Healthcare | 1 | $19 |
| Amgen | 1 | $18 |
| Novartis | 1 | $17 |
| Gilead | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Breas Medical, Inc. | 1 | $15 |
How this compares
$234,800 in reported general payments places this provider in the 90th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Orenitram ErTreprostinil Diolamine | 38 | $562,095 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 321 | $277,235 |
| OfevNintedanib Esylate | 21 | $254,362 |
| AdempasRiociguat | 13 | $183,162 |
| OpsumitMacitentan | 13 | $164,616 |
| Ambrisentan | 50 | $137,243 |
| NucalaMepolizumab | 25 | $87,147 |
| Spiriva RespimatTiotropium Bromide | 107 | $74,437 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 91 | $64,134 |
| Breo ElliptaFluticasone/Vilanterol | 112 | $61,792 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 89 | $60,113 |
| TezspireTezepelumab-Ekko | 11 | $46,560 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 67 | $45,912 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 31 | $20,913 |
| SymbicortBudesonide/Formoterol Fumarate | 68 | $18,398 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $44,340 | $498,682566 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $44 | $395,623226 claims |
| BayerAdempas | $31 | $183,16213 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $439 | $164,61613 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $60,684 | $125,071168 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Orlando
- Daniel LayishOrlando$1.8M
- Ali JiwaniOrlando$859K
- Syed MobinOrlando$488K
- Yitzhak Daniel HaimOrlando$486K
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.